Spondyloarthritis & psoriatic arthritis
Cancer risks in patients with ankylosing spondylitis and the effects of biologic agents: a population-based study
Main finding · Overall cancerResult — go to the resultAdjusted hazard ratio 1.1 95% CI 0.93–1.31Authors' conclusion
The overall cancer risk in patients with AS was not significantly different compared with that in the controls. However, while the effect of NSAIDs on upper GI cancer cannot be ruled out, patients with AS exhibited a significant increase in the risk of both upper GI cancer and haematologic malignancy.
Study context
- Population
- Patients with AS and matched controls from the Korea National Health Insurance Service-National Sample Cohort database, 2002–2019matched cohort
- Participants
- 1,796 vs 7,184
- Exposure
- AS vs age- and sex-matched controls
- ASn = 1,796
- Controlsn = 7,184reference
- Outcome
- Malignancy (cancer) risk
Methodological detailspopulation-based, age- and sex-matched controls (1:4 ratio)
- Population-based
- Age- and sex-matched controls (1:4 ratio)
Main finding
Overall cancer
Adjusted hazard ratio
1.1
95% CI 0.93–1.31
Events by group
AS
9.3%
168 of 1796
ASvs Controls
aHR 1.1 (95% CI 0.93–1.31)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | |
|---|---|---|
| Upper GI cancer | 1.51 (1.07–2.12) | |
| Haematologic malignancy | 2.36 (1.2–4.65) | |
| Upper GI cancer, regarding medication for AS | 1.51 (1.00–2.29) | |
| 0.20.5125Adjusted hazard ratio (log scale) |
Other major cancers
- No significant differences between AS and controls
Original publication
Cancer risks in patients with ankylosing spondylitis and the effects of biologic agents: a population-based study. Rheumatology (Oxford). Published 12 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →